File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Frequent varicella zoster reactivation associated with therapeutic use of arsenic trioxide: Portents of an old scourge

TitleFrequent varicella zoster reactivation associated with therapeutic use of arsenic trioxide: Portents of an old scourge
Authors
Issue Date2005
PublisherMosby, Inc. The Journal's web site is located at http://www.elsevier.com/locate/jaad
Citation
Journal Of The American Academy Of Dermatology, 2005, v. 53 n. 5, p. 890-892 How to Cite?
AbstractIn 44 patients treated with arsenic trioxide (As2O3) for acute promyelocytic leukemia, 11 developed varicella zoster virus (VZV) reactivation (median 56 days [range 15-299]) after treatment. There was no preferential dermatome involvement or systemic spread. The actuarial risk of VZV reactivation at 1 year was 26%. No VZV reactivation occurred after the first year of initial treatment with As2O3. © 2005 by the American Academy of Dermatology, Inc.
Persistent Identifierhttp://hdl.handle.net/10722/76599
ISSN
2023 Impact Factor: 12.8
2023 SCImago Journal Rankings: 1.677
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorAu, WYen_HK
dc.contributor.authorKwong, YLen_HK
dc.date.accessioned2010-09-06T07:22:57Z-
dc.date.available2010-09-06T07:22:57Z-
dc.date.issued2005en_HK
dc.identifier.citationJournal Of The American Academy Of Dermatology, 2005, v. 53 n. 5, p. 890-892en_HK
dc.identifier.issn0190-9622en_HK
dc.identifier.urihttp://hdl.handle.net/10722/76599-
dc.description.abstractIn 44 patients treated with arsenic trioxide (As2O3) for acute promyelocytic leukemia, 11 developed varicella zoster virus (VZV) reactivation (median 56 days [range 15-299]) after treatment. There was no preferential dermatome involvement or systemic spread. The actuarial risk of VZV reactivation at 1 year was 26%. No VZV reactivation occurred after the first year of initial treatment with As2O3. © 2005 by the American Academy of Dermatology, Inc.en_HK
dc.languageengen_HK
dc.publisherMosby, Inc. The Journal's web site is located at http://www.elsevier.com/locate/jaaden_HK
dc.relation.ispartofJournal of the American Academy of Dermatologyen_HK
dc.rightsJournal of American Academy of Dermatology. Copyright © Mosby, Inc.en_HK
dc.subject.meshAdolescenten_HK
dc.subject.meshAdulten_HK
dc.subject.meshAgeden_HK
dc.subject.meshAntineoplastic Agents - adverse effectsen_HK
dc.subject.meshArsenicals - adverse effectsen_HK
dc.subject.meshChickenpoxen_HK
dc.subject.meshChilden_HK
dc.subject.meshFemaleen_HK
dc.subject.meshHerpes Zoster - chemically induced - epidemiologyen_HK
dc.subject.meshHumansen_HK
dc.subject.meshMaleen_HK
dc.subject.meshMiddle Ageden_HK
dc.subject.meshOxides - adverse effectsen_HK
dc.subject.meshRecurrenceen_HK
dc.titleFrequent varicella zoster reactivation associated with therapeutic use of arsenic trioxide: Portents of an old scourgeen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0190-9622&volume=53&issue=5&spage=890&epage=2&date=2005&atitle=Frequent+varicella+zoster+reactivation+associated+with+therapeutic+use+of+arsenic+trioxide:+portents+of+an+old+scourgeen_HK
dc.identifier.emailKwong, YL:ylkwong@hku.hken_HK
dc.identifier.authorityKwong, YL=rp00358en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/j.jaad.2005.07.030en_HK
dc.identifier.pmid16243151-
dc.identifier.scopuseid_2-s2.0-27144530265en_HK
dc.identifier.hkuros120148en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-27144530265&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume53en_HK
dc.identifier.issue5en_HK
dc.identifier.spage890en_HK
dc.identifier.epage892en_HK
dc.identifier.isiWOS:000232898000029-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridAu, WY=7202383089en_HK
dc.identifier.scopusauthoridKwong, YL=7102818954en_HK
dc.identifier.issnl0190-9622-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats